by | Dec 6, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers surveyed people living with systemic lupus erythematosus (SLE) to examine if demographic factors such as age, race/ethnicity, and geographic location, influence health and psychosocial burdens— including barriers to healthcare access,...
by | Dec 6, 2024 | Lupus Foundation of America, News & Events
Researchers explored the connection between systemic lupus erythematosus (SLE) and thyroid (a gland in the body that produces hormones regulating metabolism and growth) disorders and report a complex interplay of autoimmune processes between the two conditions....
by | Dec 5, 2024 | Lupus Foundation of America, News & Events
The U.S Food and Drug Administration (FDA) granted Fast Track Designation to Sana Biotechnology’s SC291 for relapsed/refractory systemic lupus erythematosus (SLE) treatment. SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T cell therapy. This...
by | Dec 5, 2024 | Lupus Foundation of America
The National Football League’s (NFL) My Cause My Cleats campaign is back for its ninth year, allowing players to turn their passion for advocacy into action. During Weeks 13 and 14 of the season, players across the league are taking the field wearing custom cleats...
by | Dec 4, 2024 | Lupus Foundation of America, News & Events
A new study published in Lupus Science & Medicine investigated the relationship between homotopic connectivity, which refers to the functional and structural connections between the hemispheres of the brain, and cognitive changes in people with systemic lupus...
by | Nov 21, 2024 | Lupus Foundation of America, News & Events
Adicet Bio announced the first person with lupus nephritis (LN) has been dosed with ADI-001, an investigational allogeneic gamma delta CAR T cell therapy that targets B cells. The phase 1 study of ADI-001 in autoimmune diseases is currently underway with preliminary...
